Akeso logs Phase III success in second tumour type for ivonescimab

Phase 3positiveivonescimabPositive

AI Analysis

Summary

Akeso announced positive Phase III results for ivonescimab in a second tumor type. The successful trial demonstrates the drug's potential across multiple cancer indications.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III success in second tumour type

Importance:7/10

Sentiment:

0.80

Phase 3OncologyClinical trialPositive data

Related Companies

$AZN

Read the original article

Published by yahoo_finance on August 26, 2026 11:29 AM

Read Original